跳至主要内容
临床试验/ACTRN12617001375347
ACTRN12617001375347已完成1 期

A Phase 1, Randomized, Placebo controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ACP-014 in Healthy Adult Subjects (ACP-014 -Phase 1)

Ascendis Pharma Bone Diseases A/S0 个研究点目标入组 186 人开始时间: 2017年9月28日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
186

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 60 Years(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

相似试验

Unknown
2 期
A clinical Study to assess the Efficacy and Safety of Ursodiol Injection in covid-19 patients
CTRI/2021/11/038307Shilpa Medicare Limited16
进行中(未招募)
不适用
A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg in Healthy Adolescents Aged 11 to 18 YearsThe test is a vaccine. The subjects are healthy adolescents.MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestations
EUCTR2008-007789-51-PLPfizer Inc715
进行中(未招募)
不适用
A clinical study to test the safety and immune response of a vaccine against a bacteria causing meningitis B at doses of 60 µg, 120 µg, and 200 µg in healthy adolescents aged 11 to 18 YearsPrevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.MedDRA version: 17.1Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 100000004862
EUCTR2008-007789-51-Outside-EU/EEAWyeth Research Division of Wyeth Pharmaceuticals Inc.539
已完成
1 期
To evaluate safety and tolerability after multiple oral doses of AZD1656 in type 2 diabetes patients on top of metformi
CTRI/2009/091/000774AstraZeneca AB, 151 85 Södertälje, Sweden24
进行中(未招募)
1 期
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignanciesMedDRA version: 17.1Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-003812-36-ESMorphotek Inc214